Melanie Nallicheri - EQRx CEO Director
| EQRXDelisted Stock | USD 1.83 0.13 6.63% |
Insider
Melanie Nallicheri is CEO Director of EQRx Inc
| Age | 54 |
| Phone | 617 315 2255 |
| Web | https://www.eqrx.com |
EQRx Management Efficiency
The company has return on total asset (ROA) of (0.1379) % which means that it has lost $0.1379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2025) %, meaning that it created substantial loss on money invested by shareholders. EQRx's management efficiency ratios could be used to measure how well EQRx manages its routine affairs as well as how well it operates its assets and liabilities.EQRx Inc currently holds 3.83 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. EQRx Inc has a current ratio of 28.18, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about EQRx's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Fischbach | Revolution Medicines | 43 | |
| Alexis AM | Blueprint Medicines Corp | 52 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Keith MBA | Keros Therapeutics | 54 | |
| DPhil DPHIL | Kymera Therapeutics | 48 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Elizabeth Montgomery | Black Diamond Therapeutics | 52 | |
| Johannes Hull | Pliant Therapeutics | 49 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Jasbir Seehra | Keros Therapeutics | 68 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| Dean MD | Pliant Therapeutics | N/A | |
| Sergey MD | Black Diamond Therapeutics | 55 | |
| Bruce CFA | Kymera Therapeutics | N/A | |
| Sunil MD | Sana Biotechnology | 54 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 |
EQRx Inc Leadership Team
Elected by the shareholders, the EQRx's board of directors comprises two types of representatives: EQRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EQRx. The board's role is to monitor EQRx's management team and ensure that shareholders' interests are well served. EQRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EQRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Hoey, Chief Operations | ||
| Robert LLB, CoFounder Advisor | ||
| Alexis AM, Founder Directors | ||
| MAPP MD, CoFounder Advisor | ||
| Jamilu Rubin, Chief Officer | ||
| Sir CBE, CoFounder Advisor | ||
| Rona Anhalt, Chief Officer | ||
| Eric MD, Chief Exec | ||
| Melanie Nallicheri, CEO Director | ||
| Dina JD, Gen Sec |
EQRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EQRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (75.06 M) | |||
| Shares Outstanding | 487.7 M | |||
| Shares Owned By Insiders | 11.13 % | |||
| Shares Owned By Institutions | 68.24 % | |||
| Number Of Shares Shorted | 11.3 M | |||
| Price To Book | 1.00 X | |||
| EBITDA | (517.58 M) | |||
| Net Income | (169.09 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in EQRx Stock
If you are still planning to invest in EQRx Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EQRx's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |